Siremadlin
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Panobinostat Novartis Pharmaceuticals | Phase 1 | CC |
Everolimus Novartis Pharmaceuticals | Phase 1 | CC |
lcl161 Novartis Pharmaceuticals | Phase 1 | CC |
qbm076 Novartis Pharmaceuticals | Phase 1 | CC |
Spartalizumab Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
Siremadlin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →